Silver Book Fact

Treatment of patients with advanced dry age-related macular degeneration (AMD) with ciliary neurotrophic factor (CNTF) implants resulted in stabilization of visual acuity.  A sub-group analysis found that 100% of patients receiving a high-dose lost <15 letters of acuity–compared with 55.6% in the combined low-dose/sham group.  The high-dose group had a 0.6 mean letter gain while the low-dose/sham group had a mean 9.7 letter loss.

Zhang K, Hopkins J, Heier J, Birch D, et al. Ciliary Neurotrophic Factor Delievered by Encapsulated Cell Intraocular Implants for Treatment of Geographic Atrophy in Age-Related Macular Degeneration. PNAS. 2011; 108(15). http://www.pnas.org/content/early/2011/03/24/1018987108

Reference

Title
Ciliary Neurotrophic Factor Delievered by Encapsulated Cell Intraocular Implants for Treatment of Geographic Atrophy in Age-Related Macular Degeneration
Publication
PNAS
Publication Date
2011
Authors
Zhang K, Hopkins J, Heier J, Birch D, et al
Volume & Issue
Volume 108, Issue 15
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Timely treatment and follow-up care can reduce the risk of blindness in individuals with proliferative retinopathy by 95%.  
  • It has been estimated that monthly use of ranibizumab in individuals with age-related macular degeneration (AMD) would reduce the incidence of legal blindness by 72% and visual impairment by 37%,…  
  • The NEI-sponsored Age-Related Eye Disease Study (AREDS) found that individuals at high risk of developing advanced stages of age-related macular degeneration (AMD) lowered their risk of disease progression by about…  
  • Prescription eye drops could delay or prevent half of glaucoma cases in African Americans.  
  • Screening and treatment for eye disease in all type 2 diabetes patients would result in an estimated net savings of 94,304 person-years of sight.